| Autor: |
Baryshnikov AYu; Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia., Polosukhina ER, Tupitsin NN, Gavrikova NV, Andreeva LYu, Zabotina TN, Mayakova SA, Kurmashov VI, Syrkin AB, Kadagidze ZG, Blochin DYu, Shishkin YuV |
| Jazyk: |
angličtina |
| Zdroj: |
Advances in experimental medicine and biology [Adv Exp Med Biol] 1999; Vol. 457, pp. 251-8. |
| DOI: |
10.1007/978-1-4615-4811-9_27 |
| Abstrakt: |
We analyzed CD95(Fas/APO-1) antigen expression on bone marrow blasts in 38 children with acute lymphoblastic leukemia (ALL) receiving a treatment in the Department of Leukaemias at the Cancer Research Center in 1987-1989 years (n = 22) and in 1994-1997 years (n = 16). CD95 antigen expression was studied by monoclonal antibodies (MoAbs) IPO-4 in indirect immunofluorescence analysis. CD95 antigen was expressed on 35.8 +/- 7.5% bone marrow blasts, most frequently (63.6%) in the clinically favourable Pre-B ALL. Only in this group CD95 antigen expression was correlated with CD10 antigen expression that has a positive influence to the time of complete remission in ALL patients. Our data showed that CD95 expression on blast cells is a favourable prognostic sign, associated with increased relapse-free and total survival. On the contrary, the absence of CD95 antigen on blasts is an unfavourable sign for disease evolution. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
